Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Steatotic liver disease often progresses asymptomatically, with the risk of advancing to cirrhosis and liver cancer. Early detection of advanced liver disease through screening presents an opportunity ...

Does colchicine work for CVD or doesn’t it? That’s the question the study authors hoped to answer, but there’s little ...

Atopic dermatitis (AD) was associated with an increased risk for chronic kidney disease (CKD) in an Asian population, ...

A recent study led by Paul DeCaen, Ph.D., associate professor of Pharmacology, has identified novel molecular mechanisms by ...

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

Long-term exposure to water contaminants, even below the regulatory limits, significantly increases the risk of chronic ...

Finerenone may lower risks for kidney and cardiovascular events for adults with chronic kidney disease and type 2 diabetes, ...

AstraZeneca said on Monday its experimental drug baxdrostat significantly lowered blood pressure in a late-stage trial of ...